Deutsche Bank analyst Pito Chickering raised the firm’s price target on Boston Scientific to $63 from $55 and keeps a Hold rating on the shares. The company received Farapulse FDA approval but also a “big setback” in U.S. transcatheter heart valves, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- Boston Scientific Announces Key Executive Appointments
- Boston Scientific (NYSE:BSX) Surges on Stellar Q4 Results
- Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
- Boston Scientific sees FY24 adjusted EPS $2.23-$2.27, consensus $2.24
- Boston Scientific sees Q1 EPS 50c-52c, consensus 52c
